• Veradermics' VDPHL01 met both co-primary efficacy endpoints with high statistical significance in two registration-directed male pattern hair loss studies.
• Twice-daily dosing increased six-month target area hair counts by 36.4 in Study 304 versus 6.6 with placebo.
• Study 302 recorded corresponding increases of 33.0 versus 7.3 with placebo.
• Patient-reported improvement rates with twice-daily dosing reached 68.7% in Study 304 versus 62.9% in Study 302.
• The female Phase 2/3 trial is fully enrolled with 556 participants; initial topline data are expected in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.